Integrin mediated-ECM (extracellular matrix) remo
deling is one of the critical steps on
vascular re-construction in specifi
c pathological condition including ischemic vascular disease,
because ECM provides a stable environment for cell growth, diff
erentiation and migration.
er massive ischemic injury on blood vessels, cell transplantation using stem cell source into
injured ischemic region can improve vascular function through cell engraft
ment and forming
neo-vessels on injured site.
In this study, we derived vascular angiogenic progenitor cell population from hESC (hESC-
VAPCs) and investigate their therapeutic eff
ect and unique therapeutic mechanism on hindlimb
ischemia disease model.
As the result, hESC-VAPCs were retaining representative vascular characteristics in vitro
and therapeutic eff
ect on hindlimb ischemic model mouse. Blood perfusion rate on hESC-
VAPCs transplanted group was signifi
cantly improved than cord bold derived EPCs (CB-EPCs)
and vehicle medium injection transplantation group. Furthermore, to fi
ne out the therapeutic
mechanism of hESC-VAPCs, we applied proteomic analysis tool between hESC-VAPCs and
EPCs. Interestingly for this study, we could confi
rm that main therapeutic behavior was caused
by up-regulated participation of several ECM
and integrin mediated signaling pathway in
Together, these data suggest hESC-VAPCs could be a valuable novel cellular source for
therapeutic treatment of vascular ischemic disease due to their participation of up-regulated
several ECM molecules and integrin mediated pathway.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals